Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin

Future Oncology

Volumn 13, Issue 25, 2017, Pages 2233-2242

  Paul, Shilpa ^a   Rausch, Caitlin R ^a   Kantarjian, Hagop ^a   Jabbour, Elias J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute lymphoblastic leukemia; inotuzumab; monoclonal antibody; relapsed disease

Indexed keywords

BENDAMUSTINE; BOSUTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INOTUZUMAB OZOGAMICIN; LIVER ENZYME; MITOXANTRONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CD22 ANTIGEN; CD22 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEBRILE NEUTROPENIA; HUMAN; HYPERBILIRUBINEMIA; LIVER VENOOCCLUSIVE DISEASE; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ADULT; AGE; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; SIALIC ACID BINDING IG-LIKE LECTIN 2; TREATMENT OUTCOME;

EID: 85034113425     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2017-0233     Document Type: Article

References (28)

1. Jabbour E, O'Brien SM, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121(15), 2517-2528 (2015).
2. Short NJ, Kantarjian HM, O'Brien SM et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): interim result of a Phase II clinical trial. Presented at: American Society of Clinical Oncology 2017 Annual Meeting. IL, USA, 2-6 June 2017.
3. Piccaluga PP, Arpinati M, Candoni A et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk. Lymphoma 52(2), 325-327 (2011).
4. Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur. J. Haematol. 98(5), 425-434 (2017).
5. de Vries JF, Zwaan CM, De Bie M et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 26(2), 255-264 (2012).
6. DiJoseph JF, Armellino DC, Boghaert ER et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5), 1807-1814 (2004).
7. Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol. Immunol. 67(2 Pt A), 107-116 (2015).
8. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21(11), 2240-2245 (2007).
9. Kantarjian H, Thomas D, Jorgensen J et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119(15), 2728-2736 (2013).
10. Kantarjian H, Thomas D, Jorgensen J et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a Phase II study. Lancet Oncol. 13(4), 403-411 (2012).
11. Jabbour E, O'Brien SM, Huang X et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am. J. Hematol. 90(3), 193-196 (2015).
12. Advani AS, Stein AS, Kantarjian HM et al. A Phase II study of weekly inotuzumab ozogamicin (InO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage. Blood 124(21), 2255-2255 (2014).
13. Kantarjian HM, DeAngelo DJ, Stelljes M et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375(8), 740-753 (2016).
14. Jabbour E, Advani A, Stelljes M et al. Prognostic implications of pre-treatment cytogenetics in adults with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Presented at: The 22nd Congress of European Hematology Association. Madrid, Spain, 22-25 June 2017.
15. DeAngelo D, Jabbour E, Stelljes M et al. Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the Phase III INO-VATE trial: efficacy and safety by prior therapy. J. Clin. Oncol. 34(15-Suppl.), Abstract 7028 (2016).
16. Jabbour E, Advani A, Stelljes M et al. Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the Phase III INO-VATE trial. J. Clin. Oncol. 34(Suppl.), Abstract 7029 (2016).
17. Kantarjian HM, O'Brien SM, Smith TL et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J. Clin. Oncol. 18(3), 547-561 (2000).
18. Sasaki K, Kantarjian HM, O'Brien SM et al. Salvage chemotherapy with inotuzumab ozogamicin (ino) combined with mini-hyper-cvd for adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Blood 126(23), 3721 (2015).
19. Jabbour E, O'Brien SM, Sasaki K et al. Frontline inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-cvd) for older patients with acute lymphoblastic leukemia (ALL). Blood 126(23), 83 (2015).
20. Giles FJ, Kantarjian HM, Kornblau SM et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92(2), 406-413 (2001).
21. McKoy JM, Angelotta C, Bennett CL et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk. Res. 31(5), 599-604 (2007).
22. Godwin CD, McDonald GB, Walter RB. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood 129(16), 2330-2332 (2017).
23. Guffroy M, Falahatpisheh H, Biddle K et al. Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys-mechanism and monitoring. Clin. Cancer Res. 23(7), 1760-1770 (2017).
24. Richardson PG, Riches ML, Kernan NA et al. Phase III trial of defibrotide for the treatment of veno-occlusive disease and multi-organ failure. Blood 127, 1656-1665 (2016).
25. Matsui H, Takeshita A, Naito K et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 16(5), 813-819 (2002).
26. Takeshita A, Shinjo K, Yamakage N et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br. J. Haematol. 146(1), 34-43 (2009).
27. Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7, 27-34 (2013).
28. Jabbour E, Short NJ, Jorgensen JL et al. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2), 294-302 (2017).